Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02001389 · ClinicalTrials.gov registry record · Phase 1
Study of EVP-6308 to Assess the Dose- and Concentration-dependent Displacement of [18F]MNI-659 by EVP-6308
A Phase 1 study, sponsored by FORUM Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 14
- Enrollment target
NCT02001389 is a Phase 1 study that has completed, run by FORUM Pharmaceuticals. The registered enrollment target is 14 participants.
The verdict
NCT02001389, a Phase 1 study, has completed, sponsored by FORUM Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 14 participants
- Enrollment target
Study Summary
This is an open-label, single-arm, multiple ascending dose Phase I study to assess the dose- and concentration-dependent displacement of \[18F\]MNI-659 \[a PET tracer targeting phosphodiesterase 10 (PDE10)\] by EVP-6308.
Interventions
- DRUG EVP-6308
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 14 participants |
| Start Date | 2013-10 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02001389
The ClinicalTrials.gov registry entry for NCT02001389 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 14 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is FORUM Pharmaceuticals, which has 13 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which EVP-6308 is the first listed.
NCT02001389 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02001389 about?
NCT02001389 is a clinical study titled "Study of EVP-6308 to Assess the Dose- and Concentration-dependent Displacement of [18F]MNI-659 by EVP-6308". This is an open-label, single-arm, multiple ascending dose Phase I study to assess the dose- and concentration-dependent displacement of \[18F\]MNI-659 \[a PET tracer targeting phosphodiesterase 10 (PDE10)\] by EVP-6308.
What is the current status of trial NCT02001389?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 14 participants. The study started on 2013-10.
What interventions are being tested in trial NCT02001389?
The interventions under investigation include: EVP-6308 (DRUG).
Who is sponsoring clinical trial NCT02001389?
This trial is sponsored by FORUM Pharmaceuticals, which has 13 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.